Evidence map›Paper›PMID 28364292›Full record

ArticleJournal of neurology2017

Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients.

Ángel Sesar, Gustavo Fernández-Pajarín, Begoña Ares, María Teresa Rivas, Alfonso Castro

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Observational
  11. Article
  12. Monotherapy with infusion therapies - useful or not?Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  13. Observational
  14. Article
  15. Observational
  16. Current and novel infusion therapies for patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2023
    Review
  17. Review
  18. Night-Time Apomorphine Infusion: Who Are the Best Candidates?Movement disorders clinical practice · 2023
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ángel SesarDepartment of Neurology, Movement Disorder Clinic, Complejo Hospitalario Universitario de Santiago de Compostela, 15706, Santiago de Compostela, Spain. angel.sesar.ignacio@sergas.es.
Gustavo Fernández-PajarínDepartment of Neurology, Movement Disorder Clinic, Complejo Hospitalario Universitario de Santiago de Compostela, 15706, Santiago de Compostela, Spain.
Begoña AresDepartment of Neurology, Movement Disorder Clinic, Complejo Hospitalario Universitario de Santiago de Compostela, 15706, Santiago de Compostela, Spain.
María Teresa RivasDepartment of Neurology, Movement Disorder Clinic, Complejo Hospitalario Universitario de Santiago de Compostela, 15706, Santiago de Compostela, Spain.
Alfonso CastroDepartment of Neurology, Movement Disorder Clinic, Complejo Hospitalario Universitario de Santiago de Compostela, 15706, Santiago de Compostela, Spain.
Complejo Hospitalario Universitario de Santiago · ESComplexo Hospitalario Universitario A Coruña · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Continuous apomorphine infusion (APO) is one of the treatments available for advanced Parkinson disease (PD). Over 10 years, we have treated 230 patients with APO. Mean age was 66.8 and average evolution time at APO onset was 13.0 years. Mean duration of the treatment was 26.3 months. As of June 2016, 93 remained on the medication (active group), while 137 had stopped. This active group had mean age 67.3 at recruitment and mean evolution 14.2 years. The main indication for APO was lack of deep brain stimulation criteria (DBS). Twelve patients were on waiting list for DBS. Average time since APO onset was 40.0 months. In the active group, APO decreased off-state in 4 h and allowed reducing levodopa and dopamine agonists. Dyskinesia and balance did not worsen. Cognitive decline did not change within the first 15 months. Hallucinations were the same within the first 39 months. The presence of subcutaneous nodules was the most frequent adverse event in this group. The main reason for discontinuation was side effects, being psychosis the most common. Within the first year, 82 patients stopped APO. Eighteen of these patients eventually got DBS. APO is a good option for advanced PD, since it permits a significant reduction in off-time and other antiparkinsonian drugs. This effect is sustained over time. We have treated 132 patients for over a year. Dyskinesia seems not to worsen. Combining APO with DBS simultaneously or alternatively provides good results.

Indexed as

AdultAgedAged, 80 and overApomorphineCognition DisordersCohort StudiesDopamine AgonistsDyskinesiasFemaleHumansInfusions, SubcutaneousMaleMiddle AgedParkinson DiseaseSensation DisordersSeverity of Illness IndexApomorphineDopamine AgonistsAdvanced stageApomorphineLong-term therapyParkinson’s diseaseTreatment

Identifiers

PMID28364292
OpenAlexW2601318788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.